Kinase activation in circulating cells: opportunities for biomarkers for diagnosis and therapeutic monitoring

Bibliography

• Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986;233(4760):212-4
   PubMed Web of Science ®Google Scholar
• Leibowitz D, Young KS. The molecular biology of CML: a review. Cancer Invest 1989;7(2):195-203
   PubMed Web of Science ®Google Scholar
• Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243(5405):290-3
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Capdeville R, et al. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2001:87-112
   PubMedGoogle Scholar
• Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007;109(11):2171-81
   PubMed Web of Science ®Google Scholar
• Srivastava S, Gopal-Srivastava R. Biomarkers in cancer screening: a public health perspective. J Nutr 2002;132(8):2471S-2475S
   PubMed Web of Science ®Google Scholar
• Barker PE. Cancer biomarker validation: standards and process – roles for the National Institute of Standards and Technology (NIST). Epigenetics in Cancer Prevention: Early Detection and Risk Assessment; 2003. p. 142-50
   Google Scholar
• Pritzker KPH. Cancer biomarkers: easier said than done. Clin Chem 2002;48(8):1147-50
   PubMed Web of Science ®Google Scholar
• Degos L, Linch DC, Lowenberg B. Textbook of Malignant Hematology Martin Dunitz. London; 1999
   Google Scholar
• Mocellin S, Keilholz U, Rossi CR, Nitti D. Circulating tumor cells: the ‘leukemic phase’ of solid cancers. Trends Mol Med 2006;12(3):130-9
   PubMed Web of Science ®Google Scholar
• Grisham MB, Engerson TD, Mccord JM, Jones HP. A comparative study of neutrophil purification and function. J Immunol Methods 1985;82(2):315-20
   PubMed Web of Science ®Google Scholar
• Glasser L, Fiederlein RL. The effect of various cell separation procedures on assays of neutrophil function. A critical appraisal. Am J Clin Pathol 1990;93(5):662-9
   PubMed Web of Science ®Google Scholar
• Herzenberg LA, Parks D, Sahaf B, et al. The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin Chem 2002;48(10):1819-27
   PubMed Web of Science ®Google Scholar
• Haukanes BI, Kvam C. Application of magnetic beads in bioassays. Biotechnology (NY) 1993;11(1):60-3
   PubMedGoogle Scholar
• Abraham E. Alterations in cell signaling in sepsis. Clin Infect Dis 2005;41:S459-64
   PubMed Web of Science ®Google Scholar
• Okutani D, Lodyga M, Han B, Liu MY. Src protein tyrosine kinase family and acute inflammatory responses. Am J Physiol Lung Cell Mol Physiol 2006;291(2):L129-41
   PubMed Web of Science ®Google Scholar
• Lowell CA, Berton G. Resistance to endotoxic shock and reduced neutrophil migration in mice deficient for the Src-family kinases Hck and Fgr. Proc Natl Acad Sci USA 1998;95(13):7580-4
   PubMed Web of Science ®Google Scholar
• Punt CJ, Rijksen G, Vlug AM, Dekker AW, Staal GE. Tyrosine protein kinase activity in normal and leukaemic human blood cells. Br J Haematol 1989;73(1):51-6
   PubMed Web of Science ®Google Scholar
• Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002;16(7):1207-12
   PubMed Web of Science ®Google Scholar
• Wadleigh M, Deangelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematofogic malignancies. Blood 2005;105(1):22-30
   PubMed Web of Science ®Google Scholar
• Lacronique V, Boureux A, Monni R, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood 2000;95(6):2076-83
   PubMed Web of Science ®Google Scholar
• Lacronique V, Boureux A, Dellavalle V, et al. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia. Science 1997;278(5341):1309-12
   PubMed Web of Science ®Google Scholar
• Bench AJ, Erber WN, Scott MA. Molecular genetic analysis of haematological malignancies: I. Acute leukaemias and myeloproliferative disorders. Clin Lab Haematol 2005;27(3):148-71
   PubMedGoogle Scholar
• Aaronson DS, Horvath CM. A road map for those who don't know JAK-STAT. Science 2002;296(5573):1653-5
   PubMed Web of Science ®Google Scholar
• Keating AK, Salzberg DB, Sather S, et al. Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 2006;25(45):6092-100
   PubMed Web of Science ®Google Scholar
• Derksen PWB, DE Gorter DJJ, Meijer HP, et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 2003;17(4):764-74
   PubMed Web of Science ®Google Scholar
• Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood 2003;101(12):4667-79
   PubMed Web of Science ®Google Scholar
• Srinivasa SP, Doshi P. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 2002;16(2):244-53
   PubMed Web of Science ®Google Scholar
• Mayer IA, Verma A, Grumbach IM, et al. The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 2001;276(30):28570-7
   PubMed Web of Science ®Google Scholar
• Pendergast AM. The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 2002;85:51-100
   PubMed Web of Science ®Google Scholar
• Boudeau J, Miranda-Saavedra D, Barton GJ, Alessi DR. Emerging roles of pseudokinases. Trends Cell Biol 2006;16(9):443-52
   PubMed Web of Science ®Google Scholar
• Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Biol 2000;20(10):3387-95
   PubMed Web of Science ®Google Scholar
• Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002;277(49):47954-63
   PubMed Web of Science ®Google Scholar
• Ho JMY, Beattie BK, Squire JA, Frank DA, Barber DL. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling. Blood 1999;93(12):4354-64
   PubMed Web of Science ®Google Scholar
• Xie SH, Wang Y, Liu JX, et al. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation. Oncogene 2001;20(43):6188-95
   PubMed Web of Science ®Google Scholar
• Coppo P, Flamant S, De Mas V, et al. BCR-ABL activates STAT3 via JAK and MEK pathways in human cells. Br J Haematol 2006;134(2):171-9
   PubMed Web of Science ®Google Scholar
• Sacha T, Hochhaus A, Hanfstein B, et al. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leuk Res 2003;27(12):1163-6
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102(1):276-83
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Parkinson I, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify imatinib-treated patients with CML who have BCR-ABL kinase domain mutations. Blood 2004;104(9):2926-32
   PubMed Web of Science ®Google Scholar
• Wu D, Nair-Gill E, Sher DA, et al. Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads. Anal Biochem 2005;347(1):67-76
   PubMed Web of Science ®Google Scholar
• Parker LL, Kron SJ. Proteomic technologies for clinical management of imatinib resistance in chronic myeloid leukemia. AACR Education Book; 2007. p. 93-9
   Google Scholar
• Epner E, Jing H, Jin W, Fleming WH. Mantle cell lymphoma: an epigenetic disease of cyclin D1 deregulation involving nucleophosmin, CTCF and small RNA's. Blood 2006;108(11):633A
   Google Scholar
• Pelech S. Tracking cell signaling protein expression and phosphorylation by innovative proteomic solutions. Curr Pharm Biotechnol 2004;5(1):69-77
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Edmiston KH, Liotta LA, Petricoin EF. Technology insight: pharmacoproteomics for cancer – promises of patient-tailored medicine using protein microarrays. Nat Clin Pract Oncol 2006;3(5):256-68
   PubMedGoogle Scholar
• Laufer S, Linsenmaier S. Development of a microsphere-based p38a MAP kinase no-wash assay. J Biomol Screen 2006;11(5):528-36
   PubMed Web of Science ®Google Scholar
• Ni Q, Titov DV, Zhang J. Analyzing protein kinase dynamics in living cells with FRET reporters. Methods 2006;40(3):279-86
   PubMed Web of Science ®Google Scholar
• Irish JM, Kotecha N, Nolan GP. Innovation – MAPPING normal and cancer cell signalling networks: towards single-cell proteomics. Nat Rev Cancer 2006;6(2):146-55
   PubMed Web of Science ®Google Scholar
• Ogata Y, Hepplmann CJ, Charlesworth MC, et al. Elevated levels of phosphorylated fibrinogen-alpha-isoforms and differential expression of other post-translationally modified proteins in the plasma of ovarian cancer patients. J Proteome Res 2006;5(12):3318-25
   PubMed Web of Science ®Google Scholar
• Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF, Liotta L. Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. In: New Trends in Cancer for the 21st Century. 2003. p. 59-68
   Google Scholar
• Morandell S, Stasyk T, Grosstessner-Hain K, et al. Phosphoproteomics strategies for the functional analysis of signal transduction. Proteomics 2006;6(14):4047-56
   PubMed Web of Science ®Google Scholar
• Stasyk T, Morandell S, Bakry R, et al. Quantitative detection of phosphoproteins by combination of two-dimensional difference gel electrophoresis and phosphospecific fluorescent staining. Electrophoresis 2005;26(14):2850-4
   PubMed Web of Science ®Google Scholar
• Kristjansdottir K, Rudolph J. A fluorescence polarization assay for native protein substrates of kinases. Anal Biochem 2003;316(1):41-9
   PubMed Web of Science ®Google Scholar
• Seethala R, Menzel R. A fluorescence polarization competition immunoassay for tyrosine kinases. Anal Biochem 1998;255(2):257-62
   PubMed Web of Science ®Google Scholar
• Diaz-Mochon JJ, Tourniaire G, Bradley M. Microarray platforms for enzymatic and cell-based assays. Chem Soc Rev 2007;36(3):449-57
   PubMed Web of Science ®Google Scholar
• Hall DA, Ptacek J, Snyder M. Protein microarray technology. Mech Ageing Dev 2007;128(1):161-7
   PubMed Web of Science ®Google Scholar
• Jalal S, Kindrachuk J, Napper S. Phosphoproteome and kinome analysis: unique perspectives on the same problem. Curr Anal Chem 2007;3(1):1-15
   Web of Science ®Google Scholar
• Andresen H, Grotzinger C, Zarse K, et al. Functional peptide microarrays for specific and sensitive antibody diagnostics. Proteomics 2006;6(5):1376-84
   PubMed Web of Science ®Google Scholar
• Ptacek J, Devgan G, Michaud G, et al. Global analysis of protein phosphorylation in yeast. Nature 2005;438(7068):679-84
   PubMed Web of Science ®Google Scholar
• Saxinger C, Conrads TP, Goldstein DJ, Veenstra TD. Fully automated synthesis of (phospho) peptide arrays in microtiter plate wells provides efficient access to protein tyrosine kinase characterization. BMC Immunol 2005;6(1):1
   PubMedGoogle Scholar
• Hutti JE, Jarrell ET, Chang JD, et al. A rapid method for determining protein kinase phosphorylation specificity. Nat Methods 2004;1(1):27-9
   PubMed Web of Science ®Google Scholar
• Brueggemeier SB, Wu D, Kron SJ, Palecek SP. Protein-acrylamide copolymer hydrogels for array-based detection of tyrosine kinase activity from cell lysates. Biomacromolecules 2005;6(5):2765-75
   PubMed Web of Science ®Google Scholar
• Green KD, Pflum MKH. Kinase-catalyzed biotinylation for phosphoprotein detection. J Am Chem Soc 2007;129(1):10-1
   PubMed Web of Science ®Google Scholar
• Parker LL, Schilling AB, Kron SJ, Kent SBH. Optimizing thiophosphorylation in the presence of competing phosphorylation with MALDI-TOF-MS detection. J Proteome Res 2005;4(5):1863-6
   PubMed Web of Science ®Google Scholar
• Jeong S, Nikiforov TT. Kinase assay based on thiophosphorylation and biotinylation. Biotechniques 1999;27(6):1232-8
   PubMed Web of Science ®Google Scholar
• Sun IY, Allfrey VG. In vivo thiophosphorylation of chromosomal proteins. Recovery and analysis of HeLa histones and derivative phosphopeptides. J Biol Chem 1982;257(3):1347-53
   PubMed Web of Science ®Google Scholar
• Kwon SW, Kim SC, Jaunbergs J, Falck JR, Zhao Y. Selective enrichment of thiophosphorylated polypeptides as a tool for the analysis of protein phosphorylation. Mol Cell Proteomics 2003;2(4):242-7
   PubMed Web of Science ®Google Scholar
• Allen JJ, Lazerwith SE, Shokat KM. Bio-orthogonal affinity purification of direct kinase substrates. J Am Chem Soc 2005;127(15):5288-9
   PubMed Web of Science ®Google Scholar
• Hale MB, Nolan GP. Phospho-specific flow cytometry: intersection of immunology and biochemistry at the single-cell level. Curr Opin Mol Ther 2006;8(3):215-24
   PubMed Web of Science ®Google Scholar
• Irish JM, Czerwinski DK, Nolan GP, Levy R. Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol 2006;177(3):1581-9
   PubMed Web of Science ®Google Scholar
• Danna EA, Nolan GP. Transcending the biomarker mindset: deciphering disease mechanisms at the single cell level. Curr Opin Chem Biol 2006;10(1):20-7
   PubMed Web of Science ®Google Scholar
• Wright GL, Cazares LH, Leung SM, et al. Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 1999;2(5-6):264-76
   PubMed Web of Science ®Google Scholar
• Chong BE, Lubman DM, Miller FR, Rosenspire AJ. Rapid screening of protein profiles of human breast cancer cell lines using non-porous reversed-phase high performance liquid chromatography separation with matrix-assisted laser desorption/ionization time-of-flight mass spectral analysis. Rapid Commun Mass Spectrom 1999;13(18):1808-12
   PubMed Web of Science ®Google Scholar
• Oehr P. ‘Omics’-based imaging in cancer detection and therapy. Personalized Med 2006;3(1):19-32
   Web of Science ®Google Scholar
• Cho WCS. Contribution of oncoproteomics to cancer biomarker discovery. Mol Cancer 2007;6:25
   PubMed Web of Science ®Google Scholar
• Ghaemmaghami S, Huh W, Bower K, et al. Global analysis of protein expression in yeast. Nature 2003;425(6959):737-41
   PubMed Web of Science ®Google Scholar
• Oda Y, Nagasu T, Chait BT. Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat Biotechnol 2001;19(4):379-82
   PubMed Web of Science ®Google Scholar
• Lim YP, Diong LS, Qi R, Druker BJ, Epstein RJ. Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells. Mol Cancer Ther 2003;2(12):1369-77
   PubMed Web of Science ®Google Scholar
• Pandey A, Andersen JS, Mann M. Use of mass spectrometry to study signaling pathways. Sci STKE 2000;2000(37):PL1
   PubMedGoogle Scholar
• Thaler F, Valsasina B, Baldi R, et al. A new approach to phosphoserine and phosphothreonine analysis in peptides and proteins: chemical modification, enrichment via solid-phase reversible binding, and analysis by mass spectrometry. Anal Bioanal Chem 2003;376(3):366-73
   PubMed Web of Science ®Google Scholar
• Thompson AJ, Hart SR, Franz C, et al. Characterization of protein phosphorylation by mass spectrometry using immobilized metal ion affinity chromatography with on-resin beta-elimination and Michael addition. Anal Chem 2003;75(13):3232-43
   PubMed Web of Science ®Google Scholar
• Adamczyk M, Gebler JC, Wu J. Selective analysis of phosphopeptides within a protein mixture by chemical modification, reversible biotinylation and mass spectrometry. Rapid Commun Mass Spectrom 2001;15(16):1481-8
   PubMed Web of Science ®Google Scholar
• Mclachlin DT, Chait BT. Improved beta-elimination-based affinity purification strategy for enrichment of phosphopeptides. Anal Chem 2003;75(24):6826-36
   PubMed Web of Science ®Google Scholar
• Bantscheff M, Eberhard D, Abraham Y, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 2007;25(9):1035-44
   PubMed Web of Science ®Google Scholar
• Thulasiraman V, Wang Z, Katrekar A, Lomas L, Yip TT. Simultaneous monitoring of multiple kinase activities by SELDI-TOF mass spectrometry. Methods Mol Biol 2004;264:205-14
   PubMedGoogle Scholar
• Parker LL, Brueggemeier SB, Rhee WJ, et al. Photocleavable peptide hydrogel arrays for MALDI-TOF analysis of kinase activity. Analyst 2006;131(10):1097-104
   PubMed Web of Science ®Google Scholar
• Chen X, Sun LW, Yu YB, Xue Y, Yang PY. Amino acid-coded tagging approaches in quantitative proteomics. Expert Rev Proteomics 2007;4(1):25-37
   PubMed Web of Science ®Google Scholar
• Putz S, Reinders J, Reinders Y, Sickmann A. Mass spectrometry-based peptide quantification: applications and limitations. Expert Rev Proteomics 2005;2(3):381-92
   PubMed Web of Science ®Google Scholar
• Heller M, Mattou H, Menzel C, Yao XD. Trypsin catalyzed O-16-to-O-18 exchange for comparative proteomics: Tandem mass spectrometry comparison using MALDI-TOF, ESI-QTOF, and ESI-Ion trap mass spectrometers. J Am Soc Mass Spectrom 2003;14(7):704-18
   PubMed Web of Science ®Google Scholar